Article: Spectrum Pharmaceuticals said patent litigation relating to sumatriptan injection--the generic version of GlaxoSmithKline's Imitrex Injection--has been dismissed by the US District Court for the District of Delaware pursuant to the previously announced settlement agreement between Spectrum and GSK.(COMPANY NEWS)

Spectrum Pharmaceuticals said patent litigation relating to sumatriptan injection--the generic version of GlaxoSmithKline's Imitrex Injection--has been dismissed by the US District Court for the District of Delaware pursuant to the previously announced settlement agreement between Spectrum and GSK. In November, Spectrum and GSK reached an agreement to settle patent litigation relating to sumatriptan injection. The terms of the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!